Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation

Therapeutic Drug Monitoring

Volumn 30, Issue 5, 2008, Pages 583-590

  Bergrem, Henrik Andreas ^a   Bergrem, Harald ^b   Hartmann, Anders ^a   Hjelmesaeth, Joeran ^c   Jenssen, Trond ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c VESTFOLD HOSPITAL TRUST   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Glucose control; Immunosuppressant pharmacokinetics; Posttransplant diabetes mellitus; Prednisolone; Renal transplantation

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FUROSEMIDE; GLUCOSE; METHYLPREDNISOLONE; PREDNISOLONE; GLUCOSE BLOOD LEVEL;

ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG PROTEIN BINDING; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT DURATION; ADULT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FOLLOW UP; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TRENDS;

ADULT; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISOLONE;

EID: 55349139717     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318187bb2f     Document Type: Article

References (51)

1. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis. 1999;34:1-13.
2. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines-Proceedings of an International Expert Panel Meeting Barcelona, Spain: 19 February 2003. Transplantation. 2003;75:SS3-SS24.
3. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979-983.
4. Oterdoom LH, de Vries AP, Gansevoort RT, et al. Determinants of insulin resistance in renal transplant recipients. Transplantation. 2007;83:29-35.
5. Boots JM, van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221-227.
6. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant. 2001;16:829-835.
7. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233-3239.
8. Rohatagi S, Earth J, Mollmann H, et al. Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol. 1997;37:916-925.
9. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40:723-751.
10. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19:126-146.
11. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583-595.
12. Hjelmesaeth J, Hagen LT, Asberg A, et al. The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Nephrol Dial Transplant. 2007;22:1743-1749.
13. Öst L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation. 1987;44:533-535.
14. van Duijnhoven EM, Boots JM, Christiaans MH, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003;16:721-725.
15. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506-1514.
16. Bergrem H, Jervell J, Flatmark A. Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Kidney Int. 1985;27:459-464.
17. Jakobsen A, Albrechtsen D, Flatmark A. Immunosuppressive therapy in Organtransplantation. Tidsskr Nor Laegeforen. 1983;103:844-847.
18. Jeng S, Chanchairujira T, Jusko W, et al. Prednisone metabolism in recipients of kidney or liver transplants and in lung recipients receiving ketoconazole. Transplantation. 2003;75:792-795.
19. Magee MH, Blum RA, Lates CD, et al. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001;41:1180-1194.
20. Mager DE, Lin SX, Blum RA, et al. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and Cortisol dynamics. J Clin Pharmacol. 2003;43:1216-1227.
21. Wilson AM, Lipworth BJ. Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Br J Clin Pharmacol. 1999;48:579-585.
22. Öst L, Bjorkhem I, Von BC. Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. Eur J Clin Pharmacol. 1984;26:363-369.
23. Keller F, Hemmen T, Schoneshofer M, et al. Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. Transplantation. 1995;60:330-333.
24. Potter JM, McWhinney BC, Sampson L, et al. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Ther Drug Monit. 2004;26:408-414.
25. Gheith OA, Bakr MA, Fouda MA, et al. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience. Clin Exp Nephrol. 2007;11:151-155.
26. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-185.
27. Roth D, Milgrom M, Esquenazi V, et al. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation. 1989;47:278-281.
28. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV impact of post-transplant diabetes. Kidney Int. 2002;62:1440-1446.
29. Ekstrand AV, Eriksson JG, Gronhagen-Riska C, et al. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation. 1992;53:563-569.
30. Hjelmesaeth J, Midtvedt K, Jenssen T, et al. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care. 2001;24:2121-2126.
31. Weir M. Impact of immunosuppressive regimes on posttransplant diabetes mellitus. Transplant Proc. 2001;33(Suppl 5A):23S-26S.
32. Delaunay F, Khan A, Cintra A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest. 1997;100:2094-2098.
33. Hollingdal M, Juhl CB, Dall R, et al. Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia. 2002;45:49-55.
34. Rhen T, Cidlowski JA. Antiinflamtnatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.
35. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
36. Bergrem H. The influence of uremia on pharmacokinetics and protein binding of prednisolone. Acta Med Scand. 1983;213:333-337.
37. Reece PA, Disney AP, Stafford I, et al. Prednisolone protein binding in renal transplant patients. Br J Clin Pharmacol. 1985;20:159-162.
38. Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and phamhacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98.
39. Bergrem H, Opedal I. Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding. Scand J Gastroenterol. 1983;18:545-549.
40. Lewis GP, Jusko WJ, Graves L, et al. Prednisone side-effects and serum-protein levels. A collaborative study. Lancet. 1971;2:778-780.
41. Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003;61:104-107.
42. Milsap RL, George DE, Szefler SJ, et al. Effect of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci. 1983;28:161-168.
43. Frey FJ. Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients. Kidney Int. 1991;39:1034-1050.
44. Kirkwood BR, Sterne JA. Regression modelling. In: Kirkwood BR, Sterne JA. Essential Medicinal Statistics. 2nd ed. Oxford, UK: Blackwell Publishing 2003:315-342.
45. Tomlinson JW, Sherlock M, Hughes B, et al. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab. 2007;92:857-864.
46. Paulsen SK, Pedersen SB, Fisker S, et al. 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity. 2007;15:1954-1960.
47. Joss N, Staatz CE, Thomson AH, et al. Predictors of new onset diabetes after renal transplantation. Clin Transpl. 2007;21:136-143.
48. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25;583-592.
49. Rodrigo E, Fernandez-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol. 2006;17:S291-S295.
50. Bonora E, Targher G, Alberiche M, et al. Predictors of insulin sensitivity in type 2 diabetes mellitus. Diabet Med. 2002;19:535-542.
51. Montori VM, Basu A, Erwin PJ, et al. Response to Hjelmesæth et al. Diabetes Care. 2002;25:1667-1668.